{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:09:19Z","timestamp":1774076959527,"version":"3.50.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005681","name":"Genesis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005681","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.det.2020.12.014","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T09:29:39Z","timestamp":1613035779000},"page":"211-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Management of Nail Psoriasis"],"prefix":"10.1016","volume":"39","author":[{"given":"Dimitrios","family":"Rigopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Rompoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stamatios","family":"Gregoriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2133.2010.09831.x","article-title":"Nail psoriasis in Germany: epidemiology and burden of disease","volume":"163","author":"Augustin","year":"2010","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1684\/ejd.2013.2048","article-title":"The impact of nail disorders on quality of life","volume":"23","author":"Belyayeva","year":"2013","journal-title":"Eur J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2020.12.014_bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2019.01.072","article-title":"Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus","volume":"81","author":"Rigopoulos","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1468-3083.2011.04349.x","article-title":"Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus","volume":"26","author":"Langley","year":"2012","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2020.12.014_bib5","series-title":"Nail disorders","author":"Tosti","year":"2018"},{"issue":"6","key":"10.1016\/j.det.2020.12.014_bib6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-016-0564-5","article-title":"Nail psoriasis: a review of treatment options","volume":"76","author":"Pasch","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.det.2020.12.014_bib7","first-page":"51","article-title":"Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management","volume":"7","author":"Haneke","year":"2017","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.det.2020.12.014_bib8","series-title":"Nail disorders","author":"Tosti","year":"2018"},{"issue":"12","key":"10.1016\/j.det.2020.12.014_bib9","first-page":"1083","article-title":"[Successful local treatment of nail psoriasis with 5-fluorouracil]","volume":"64","author":"Fritz","year":"1989","journal-title":"Z\u00a0Hautkr"},{"issue":"4","key":"10.1016\/j.det.2020.12.014_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000018281","article-title":"Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study","volume":"199","author":"de Jong","year":"1999","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.det.2020.12.014_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1346-8138.1998.tb02386.x","article-title":"Topical anthralin therapy for refractory nail psoriasis","volume":"25","author":"Yamamoto","year":"1998","journal-title":"J\u00a0Dermatol"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000068469","article-title":"Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study","volume":"206","author":"Cannav\u00f2","year":"2003","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.det.2020.12.014_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000323004","article-title":"Nail psoriasis successfully treated with intralesional methotrexate: case report","volume":"222","author":"Sar\u0131caoglu","year":"2011","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1524-4725.2009.01448.x","article-title":"Pulsed dye laser in the treatment of nail psoriasis","volume":"36","author":"Oram","year":"2010","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.det.2020.12.014_bib15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2011.12.015","article-title":"The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, intrapatient left-to-right study","volume":"66","author":"Treewittayapoom","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2020.12.014_bib16","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/jdv.13678","article-title":"Laser and light therapies for the treatment of nail psoriasis","volume":"30","author":"Maranda","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2020.12.014_bib17","doi-asserted-by":"crossref","DOI":"10.3109\/14764172.2013.854627","article-title":"Clinical trial study in the treatment of nail psoriasis with pulsed dye laser","author":"Goldust","year":"2013","journal-title":"J\u00a0Cosmet Laser Ther"},{"issue":"7","key":"10.1016\/j.det.2020.12.014_bib18","first-page":"763","article-title":"Novel treatment of nail psoriasis using the intense pulsed light: a one-year follow-up study","volume":"40","author":"Tawfik","year":"2014","journal-title":"Dermatol Surg"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/DSS.0000000000000841","article-title":"A\u00a0clinical review of laser and light therapy for nail psoriasis and onychomycosis","volume":"43","author":"Wiznia","year":"2017","journal-title":"Dermatol Surg"},{"issue":"8","key":"10.1016\/j.det.2020.12.014_bib20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1468-3083.2009.03196.x","article-title":"Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study","volume":"23","author":"Fern\u00e1ndez-Guarino","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaad.2019.04.042","article-title":"Joint American academy of dermatology-national psoriasis foundation guidelines of care for the management and treatment of psoriasis with phototherapy","volume":"81","author":"Elmets","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2020.12.014_bib22","first-page":"165","article-title":"Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability","volume":"6","author":"Abrouk","year":"2016","journal-title":"Psoriasis (Auckl)"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13555-014-0057-y","article-title":"Single blinded left-to-right comparison study of excimer laser versus pulsed dye laser for the treatment of nail psoriasis","volume":"4","author":"Al-Mutairi","year":"2014","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/DSS.0000000000001294","article-title":"Long-pulsed Nd: YAG laser treatment for nail psoriasis","volume":"44","author":"Kartal","year":"2018","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.det.2020.12.014_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1468-3083.2010.03938.x","article-title":"Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy)","volume":"25","author":"S\u00e1nchez-Rega\u00f1a","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"9494","key":"10.1016\/j.det.2020.12.014_bib26","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.det.2020.12.014_bib27","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1468-3083.2010.03927.x","article-title":"Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study","volume":"25","author":"G\u00fcm\u00fc\u015fel","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.det.2020.12.014_bib28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1365-2133.1993.tb03350.x","article-title":"Response of nail psoriasis to cyclosporin","volume":"129","author":"Arnold","year":"1993","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib29","first-page":"248","article-title":"Successful treatment of psoriatic nails with low-dose cyclosporine administration","volume":"17","author":"Syuto","year":"2007","journal-title":"Eur J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2020.12.014_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1529-8019.2012.01539.x","article-title":"Treatment of severe nail psoriasis with acitretin: an impressive therapeutic result","volume":"26","author":"Ricceri","year":"2013","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.det.2020.12.014_bib31","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1046\/j.1365-2133.2001.04189.x","article-title":"Pustular psoriasis of the nails: treatment and long-term follow-up of 46 patients","volume":"144","author":"Piraccini","year":"2001","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/09546630701264331","article-title":"Nail psoriasis improvement in a patient treated with fumaric acid esters","volume":"18","author":"Vlachou","year":"2007","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.det.2020.12.014_bib33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000478903","article-title":"Lymphopenia and CD4+\/CD8+ Cell Reduction under Fumaric Acid Esters","volume":"233","author":"Sondermann","year":"2017","journal-title":"Dermatology"},{"issue":"11","key":"10.1016\/j.det.2020.12.014_bib34","first-page":"1065","article-title":"A\u00a036-week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis","volume":"11","author":"Bardazzi","year":"2013","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jaad.2007.07.042","article-title":"Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year","volume":"58","author":"Rich","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2133.2008.08686.x","article-title":"Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study","volume":"159","author":"Rigopoulos","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000317775","article-title":"Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial","volume":"221","author":"Reich","year":"2010","journal-title":"Dermatology"},{"issue":"9","key":"10.1016\/j.det.2020.12.014_bib38","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/1346-8138.12229","article-title":"Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: an open-label, unblinded, comparative study","volume":"40","author":"Ozmen","year":"2013","journal-title":"J\u00a0Dermatol"},{"issue":"4","key":"10.1016\/j.det.2020.12.014_bib39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/14712598.2013.736960","article-title":"TNF-\u03b1 antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis","volume":"13","author":"Saraceno","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.det.2020.12.014_bib40","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/bjd.12060","article-title":"A\u00a024-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis","volume":"168","author":"Ortonne","year":"2013","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.det.2020.12.014_bib41","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1468-3083.2009.03211.x","article-title":"Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis","volume":"23","author":"Luger","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib42","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ard.2009.111856","article-title":"Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions","volume":"69","author":"Van den Bosch","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.det.2020.12.014_bib43","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1468-3083.2009.03453.x","article-title":"Treatment of nail psoriasis with adalimumab: an open label unblinded study","volume":"24","author":"Rigopoulos","year":"2010","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib44","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/jdv.12553","article-title":"Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study","volume":"29","author":"Tha\u00e7i","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2020.12.014_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaad.2017.08.029","article-title":"Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial","volume":"78","author":"Elewski","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2020.12.014_bib46","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib47","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjd.12632","article-title":"Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1","volume":"170","author":"Rich","year":"2014","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib48","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","article-title":"Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial","volume":"39","author":"Igarashi","year":"2012","journal-title":"J\u00a0Dermatol"},{"issue":"4","key":"10.1016\/j.det.2020.12.014_bib49","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000334482","article-title":"Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study","volume":"223","author":"Rigopoulos","year":"2011","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-4632.2011.05320.x","article-title":"Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients","volume":"52","author":"Vitiello","year":"2013","journal-title":"Int J Dermatol"},{"issue":"11","key":"10.1016\/j.det.2020.12.014_bib51","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/archdermatol.2010.332","article-title":"Ustekinumab for rapid treatment of nail psoriasis","volume":"146","author":"Rallis","year":"2010","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.det.2020.12.014_bib52","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jdv.12359","article-title":"Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial","volume":"28","author":"Paul","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.det.2020.12.014_bib53","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/jdv.12996","article-title":"Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis","volume":"29","author":"Langley","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.det.2020.12.014_bib54","first-page":"958","article-title":"Ixekizumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: results from UNCOVER 3","volume":"15","author":"Dennehy","year":"2016","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.det.2020.12.014_bib55","article-title":"Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3","author":"van de Kerkhof","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2020.12.014_bib56","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/CCID.S211938","article-title":"Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review","volume":"12","author":"Pinter","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"10.1016\/j.det.2020.12.014_bib57","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-018-0888-4","article-title":"Brodalumab: a review in moderate to severe plaque psoriasis","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib58","first-page":"272","article-title":"Improvement of nail and scalp psoriasis using apremilast in patients with chronic psoriasis: phase 2b and 3, 52-week randomized, placebo-controlled trial results","volume":"15","author":"Nguyen","year":"2016","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.det.2020.12.014_bib59","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2020.12.014_bib60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.det.2020.12.014_bib61","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/1346-8138.13956","article-title":"Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial","volume":"44","author":"Abe","year":"2017","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.det.2020.12.014_bib62","article-title":"Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease","author":"Reich","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1346-8138.2011.01459.x","article-title":"Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab","volume":"39","author":"Torii","year":"2012","journal-title":"J\u00a0Dermatol"},{"issue":"1","key":"10.1016\/j.det.2020.12.014_bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial","volume":"59","author":"Torii","year":"2010","journal-title":"J\u00a0Dermatol Sci"},{"issue":"4","key":"10.1016\/j.det.2020.12.014_bib65","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2004.09.012","article-title":"Remission and time of resolution of nail psoriasis during infliximab therapy","volume":"52","author":"Bianchi","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2020.12.014_bib66","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/archdermatol.2010.384","article-title":"Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial","volume":"147","author":"Leonardi","year":"2011","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.det.2020.12.014_bib67","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/jdv.15793","article-title":"Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial","volume":"33","author":"Elewski","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2020.12.014_bib68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib69","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ad.2018.02.010","article-title":"Nail psoriasis treated with certolizumab pegol in patients with psoriatic arthritis: preliminary observation","volume":"110","author":"Mazzeo","year":"2019","journal-title":"Actas Dermosifiliogr"},{"issue":"8","key":"10.1016\/j.det.2020.12.014_bib70","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.det.2020.12.014_bib71","first-page":"CD007633","article-title":"Interventions for nail psoriasis","volume":"1","author":"de Vries","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib72","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/09546634.2011.607796","article-title":"Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study","volume":"24","author":"Patsatsi","year":"2013","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.det.2020.12.014_bib73","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/09546634.2018.1476649","article-title":"Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab","volume":"30","author":"Kim","year":"2019","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib74","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13555-017-0187-0","article-title":"Guselkumab for the treatment of psoriasis: a review of phase III trials","volume":"7","author":"Nakamura","year":"2017","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.det.2020.12.014_bib75","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","article-title":"Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials","volume":"154","author":"Foley","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2020.12.014_bib76","article-title":"Effect of secukinumab on clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial","author":"Reich","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2020.12.014_bib77","doi-asserted-by":"crossref","first-page":"AB50","DOI":"10.1016\/j.jaad.2019.06.215","article-title":"Effectiveness and safety of secukinumab treatment in real-world clinical settings in European countries confirms its efficacy and safety from clinical trials: data from an interim analysis of SERENA study","volume":"81","author":"Augustin","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"sup1","key":"10.1016\/j.det.2020.12.014_bib78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/09546634.2018.1529381","article-title":"Secukinumab efficacy in the treatment of nail psoriasis: a case series","volume":"29","author":"Pistone","year":"2018","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib79","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/pde.13767","article-title":"Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis","volume":"36","author":"Wells","year":"2019","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.det.2020.12.014_bib80","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2018.05.032","article-title":"Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study","volume":"79","author":"Leonardi","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"suppl 10","key":"10.1016\/j.det.2020.12.014_bib81","article-title":"Comparison of ixekizumab and ustekinumab efficacy in the treatment of nail lesions of patients with moderate-to-severe plaque psoriasis: 24-week data from a phase 3 trial","volume":"69","author":"Ghislain","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.det.2020.12.014_bib82","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jdv.14738","article-title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study","volume":"32","author":"Reich","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2020.12.014_bib83","unstructured":"Real-World Experience With Apremilast: Analysis of 250 patients from the APPRECIATE study with psoriasis in difficult-to-treat areas. poster ID 9776 presented at the: 2019 AAD Annual Meeting; March 1, 2019, Washington, DC."},{"issue":"4","key":"10.1016\/j.det.2020.12.014_bib84","doi-asserted-by":"crossref","first-page":"AB439","DOI":"10.1016\/j.jaad.2019.10.109","article-title":"Physician- and patient-reported outcomes for patients with plaque psoriasis treated with apremilast during routine dermatology care in Germany","volume":"81","author":"Fritzlar","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2020.12.014_bib85","unstructured":"Papakonstantis M, Georgiou S, Chasapi V, et\u00a0al. Interim Results of a Nationwide, Real-World Prospective Study of the Therapeutic Effects of Apremilast on the Quality of Life and Disease Activity Parameters Among Patients With Moderate Psoriasis Treated in Greece [APRAISAL Study]. Poster ID 1641 presented at the: 28th EADV Congress 2019; September 10, 2019, Madrid."}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863520301170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863520301170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:45:23Z","timestamp":1760006723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863520301170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0733863520301170"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2020.12.014","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Nail Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2020.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}